Biocon today announced the launch of Everolimus tablets, a generic version of Afinitor, in the US, the company notified via a statement.
Everolimus tablets have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet being a ‘day-1’ generic launch. Everolimus (Afinitor) is a prescription medication that is used to treat certain types of cancers and tumours, the statement said.
The commercial launch of Everolimus follows an US FDA approval in February 2021, it added.
Speaking in this regard, Siddharth Mittal, Chief Executive Officer and Managing Director, said, “The launch of Everolimus tablets is another important addition to our generics portfolio and underscores our commitment to bringing complex, vertically-integrated and affordable generic formulations to the market expeditiously. We will continue our focus on innovation and enhancing capacities to launch new products that make affordable healthcare accessible to millions of patients the world over.”
According to the statement, the Everolimus launch is a further assertion of Biocon’s strategy to focus on vertically-integrated, complex Finished Dosage Formulations (FDF) in niche therapeutic areas, using in-house Active Pharmaceutical Ingredient (API) capabilities.
Afinitor is a registered trademark of Novartis AG, it further said.